Ocugen Inc. (US67577C1053)
XSTU 
Summary
US67577C1053 Chart
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion.
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical
Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal trial catalysts, and sufficient cash runway, despite high commercial and execution risk. Key upcoming catalysts include Phase 3 data for OCU400 and OCU410ST (Stargardt) in 2027 and a Phase 3 trial for OCU410 now FDA-cleared.
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
Ocugen Inc. (US67577C1053) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ocugen Inc. ever had a stock split?
Ocugen Inc. Profile
| Biotechnology Industry | Healthcare Sector | Shankar Musunuri CEO | XSTU Exchange | US67577C1053 ISIN |
| US Country | 116 Employees | 30 Sep 2019 Last Dividend | 30 Sep 2019 Last Split | 3 Dec 2014 IPO Date |
Overview
Ocugen, Inc. is a forward-focused clinical-stage biopharmaceutical company dedicated to pioneering the development of gene therapies aimed at eradicating blindness diseases. With its headquarters nestled in Malvern, Pennsylvania, the company is at the forefront of utilizing breakthrough technologies to create solutions for a range of inherited retinal diseases that to date have had limited treatment options. Ocugen's commitment to innovation extends beyond its therapeutic developments; it supports its ambitious goals through strategic partnerships with entities like CanSino Biologics Inc., emphasizing gene therapy co-development and manufacturing, as well as Bharat Biotech, which bolsters its commercialization strategies, notably with COVAXIN in the United States market.
Products and Services
- OCU400
OCU400 represents a significant breakthrough in the field of gene therapy, serving as a novel product candidate designed to restore retinal integrity and functionality. This innovative approach is unique in its capacity to address a broad spectrum of genetically diverse inherited retinal diseases, including retinitis pigmentosa and leber congenital amaurosis. The ambition behind OCU400 is to provide a versatile treatment option that could benefit patients suffering from various forms of retinal degeneration.
- OCU410 and OCU410ST
Targeting the prevalent condition of dry age-related macular degeneration (AMD), OCU410 and OCU410ST are at the forefront of Ocugen's pipeline, embodying the company's dedication to combatting age-related vision loss. Through cutting-edge research and development, these product candidates aspire to not only address but also ameliorate the effects of AMD, thereby improving the quality of life for those affected by this degenerative condition.
- OCU200
As a testament to Ocugen's innovative spirit, OCU200 is a novel fusion protein currently in the preclinical development stage. It stands as a potential groundbreaking treatment for diabetic macular edema, diabetic retinopathy, and wet AMD. By targeting these significant causes of blindness, OCU200 showcases the company's commitment to developing treatments that address the underlying causes of vision loss with the potential to profoundly impact patients' lives.
Contact Information
